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Objectives. This study sought o assess the independent contri- 
bution of nonfatal reinfarction to the risk of subsequent death in 
patients with acute myocardial infarction undergoing thrombo- 
lytic therapy. 
Background. A composite of "unsatisfactory outcomes" as an 
end point has increased statistical power and facilitated evalua- 
tion of evolving treatment regimens in acute myocardial infarc- 
tion. The significance of nonfatal reinfarction as a component of a 
composite nd point has not been evaluated in the thrombolytic 
era. 
Methods. Event rate of nonfatal reinfarction over 3-year 
follow-up was evaluated in patients with acute myocardial infarc- 
tion entered into the Thrombolysis in Myocardial Infarction 
Phase II trial. The independent risk of nonfatal reinfarction for 
subsequent death within various time intervals of follow-up was 
determined. The mortality rate after nonfatal reinfarction was 
compared with that of a matched control group. 
Results. During 3-year follow-up, 349 of 3,339 patients had a 
nonfatal reinfarction. Univariate predictors were history (ante- 
dating the index event) of angina (p = 0.01h hypertension (p = 
0.01), multivessel disease (p = 0.007) and not a current smoker 
(p = 0.003); the latter was an independent predictor (relative risk 
[RR] 1.3, 99% confidence interval [CI] 1.0 to 1.8). Forty-three of 
the 349 patients with a nonfatal reinfarction died: RR for death 
(vs. patients without a nonfatal reinfarction) was 1.9 (99% CI 1.1 
to 3.2) if reinfarction occurred within 42 days of study entry, 6.2 
(99% CI 3.0 to 12.9) if reinfarction occurred between 43 and 365 
days and 2.9 (99% C1 0.6 to 13.4) if reinfarction occurred between 
366 days and 3 years. The cumulative 3-year death rate was 14.1% 
in patients with a nonfatal reinfarction compared with 7.9% (p < 
0.01) in a matched control group. Univariate predictors of death 
after nonfatal reinfarction were age >65 years (p < 0.001), not 
low risk category (p = 0.015) and history of heart failure before 
the index event (p < 0.001). Age >65 years was the only 
independent predictor (RR 5.4, 99% CI 2.3 to 12.4). 
Conclusions. Nonfatal reinfarction is a strong and independent 
predictor for subsequent death. It represents a powerful compo- 
nent for a composite nd point in patients who received throm- 
bolytic therapy after acute myocardial infarction. 
(J Am Coil Cardiol 1995;26:900-7) 
The efficacy of thrombolytic therapy of acute myocardial 
infarction was initially established in placebo-controlled trials 
in which death was the primary end point (1-4). Subsequently. 
thrombolytic agents were compared with one another (5-7), as 
were combinations of thrombolytic agents with other drugs, 
including anticoagulant agents and aspirin (8,9). Further com- 
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parisons of effective treatment strategies with small differences 
in mortality require strikingly large number of patients. Recent 
trials, such as GISSI-3 (9), ISIS-4 (8) and GUSTO (7), have 
required 40,000 to almost 60,000 patients. Largely as a conse- 
quence of such trials, the mortality of patients with acute 
myocardial infarction has declined. Despite this progress, 
much can be learned with regard to optimizing thrombolytic 
regimens, in particular the role of emerging thrombolytic 
agents, specific antithrombins and newer antiplatelet regimens 
to help establish and maintain patency of the infarct-related 
artery. The role of primary and adjunctive mechanical reper- 
fusion also requires clarification. These new treatment modes 
can be administered in an almost infinite number of combina- 
tions, but it is not feasible to conduct a megatrial to evaluate 
the efficacy of every logical new therapeutic regimen. There- 
fore, to gain statistical power and allow clinically useful 
information to be obtained in reasonably sized trials, compos- 
ite end points are being used increasingly. These consist of the 
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combination of mortality with other unsatisfactory outcomes, 
including nonfatal reinfarction, heart failure, disabling stroke 
or failure to achieve patency of an occluded infarct-related 
artery (10,11). 
Recurrent myocardial infarction has been a widely used 
nonfatal end point (12-14) and was identified as a risk factor 
for subsequent mortality before the thrombolytic era (12-15). 
However, its significance in patients with thrombolytic therapy, 
in whom recurrent infarction may represent completion of an 
interrupted infarction, in particular during the early period 
after treatment, has not been defined. The present analysis of 
the Thrombolysis n Myocardial Infarction (TIMI) II (16) data 
base was undertaken todetermine the independent contribu- 
tion of nonfatal reinfarction to the risk of subsequent death of 
patients with acute myocardial infarction u dergoing throm- 
bolytic therapy. 
Methods 
Protocol. The TIMI II trial has previously been described 
in detail (16,17). Briefly, patients <76 years old who presented 
within 4 h after the onset of ischemic chest pain (>30 min) and 
who had ST segment elevations on the electrocardiogram 
(ECG) and no contraindications to thrombolytic therapy were 
eligible. All patients received intravenous infusion of recom- 
binant tissue-type plasminogen activator (rt-PA [Activase]) 
and were randomly assigned to either an invasive or a conser- 
vative strategy. The former underwent routine catheterization 
18 to 48 h after andomization a d revascularization, when the 
anatomy was appropriate. Patients assigned to the conservative 
strategy underwent these procedures only in response to 
spontaneous or provoked myocardial ischemia. Antithrom- 
botic therapy with heparin and aspirin was standardized (16). 
Beta-adrenergic blocking agent herapy was applied according 
to the design of the TIMI IIB beta-blocker substudy (18). The 
Mortality and Morbidity Classification Committee (17) re- 
viewed all reported clinical events without knowledge of 
treatment assignment and classified the events as definite 
myocardial reinfarction, recurrent ischemia or no event. 
Prespecified efinitions. "Not low risk" patient category. 
This group demonstrated the presence of one or more of the 
following: history of myocardial infarction, ST segment eleva- 
tion in anterior ECG leads, rales extending upward to more 
than one-third of the lung fields, systolic pressure < 100 mm Hg 
and sinus tachycardia > 100 beats/rain, atrial fibrillation/flutter, 
age ->70 years, pulmonary edema or cardiogenic shock (16). 
Recurrent myocardial infarction. In events occurring < ] 8 h 
after study entry, recurrent myocardial infarction was defined 
by the development of ischemic chest pain >20 min, either new 
or markedly worse chest discomfort, new plasma creatine 
kinase (CK) elevation a d appearance of CK-MB isoenzyme. 
In events occurring -> 18 h after study entry, recurrent myocar- 
dial infarction was defined by the development of new ischemic 
chest pain for >20 min and by one or more of the following: 
major new Q waves on at least wo ECG leads, new left bundle 
branch block, new plasma CK elevation and appearance of
CK-MB isoenzyme (17). A recurrent myocardial infarction was 
classified as nonfatal if the patient was discharged alive from 
the hospital after the reinfarction. 
Follow-up. Patients were enrolled from April 1986 through 
June 1988 and followed up through September 1990. Patient 
status was determined by clinic visit at 6 weeks and 1 year and 
by telephone contact at 3 months, 6 months and 2 years and, 
for patients who were enrolled in the study before September 
1987, at 3 years. Survival d ta are based on all-cause mortality 
(19). 
Statistical considerations. Event rates of nonfatal reinfarc- 
tion and death were calculated by Kaplan-Meier life-table 
methods (20,21) and compared using the log-rank test. 
To identify clinical variables that predict the occurrence of 
an initially nonfatal reinfarction, a Cox proportional hazards 
regression technique (22,23) was used. Preselected baseline 
clinical variables identified in the TIMI II Subgroup Study (24) 
were entered as predictor variables using onfatal reinfarction 
within 3 years as the outcome end point. Similar analyses were 
performed to identify clinical variables that predict subsequent 
mortality after a nonfatal reinfarction. Only patients with a 
nonfatal reinfarction (n = 349) were entered into the model. 
The same preselected clinical variables were entered as pre- 
dictor variables with death within 3 years as the outcome nd 
point. 
To determine the independent risk of subsequent death 
from nonfatal reinfarction over the 3-year follow-up period, a 
time-dependent Cox proportional hazards survival model 
(22,23) was used, adjusting for clinical baseline characteristics 
and the variability in time of occurrence of the nonfatal 
reinfarction. 
The mortality rate of patients with nonfatal reinfarction was 
compared with that of a control group. The control group 
consisted of a matched control patient for each patient with a 
nonfatal reinfarction. Matching criteria included clinical cen- 
ter, gender and decade of age. For each patient with an event, 
a pool of patients was identified who had not experienced an 
event at that time point. A matched control subject for each 
patient was randomly selected without replacement from the 
available pool. To avoid retrospective bias, the matching 
technique allowed selection f patients with later nonfatal 
reinfarction as control patients for those with early nonfatal 
reinfarction. Five independent sets of matched control groups 
were randomly selected. Comparisons f the mortality over 
time between the patients with nonfatal reinfarction and each 
of the five matched control groups were similar. A represen- 
tative control group was selected for graphical comparison 
with the nonfatal reinfarction group sing a Kaplan-Meier life 
table. 
To adjust for multiple testing, two-sided probability values 
between 0.01 and 0.001 were considered to provide some 
evidence, and values <0.001 to provide strong evidence, of 
differences. Analyses are based on a data file containing 
information available as of January 1991. 
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Resu l ts  
Patients and total clinical events. A total of 3,339 patients 
were enrolled. Vital status was known for 99.0% at 1 year and 
for 96.7% at 2 years after study entry. Of the 2,174 patients 
who were enrolled into TIMI II before September 1987, vital 
status at 3 years was ascertained to90.9%. The 2,174 patients 
enrolled before September 1987 were similar to the 1,165 
patients enrolled between October 1987 and June 1988 (19) 
and may be considered representative of the entire patient 
cohort. Follow-up for nonfatal events was obtained for 99.8% 
of patients through 6 weeks, for 98.2% of patients for 1 year, 
for 95.4% for 2 years and for 90.1% for 3 years. 
By the end of the 3-year follow-up, death from all causes 
occurred in 331 of the 3,339 patients enrolled (9.9%) and 
death or nonfatal reinfarction i 637 patients (19.1%). There 
was no difference in the incidence of events between patients 
randomized to the invasive and conservative strategy (19). 
Three hundred eighty-one (11.4%) of the 3,339 patients had  
reinfarction; in 49 of these patients (1.5 %) the reinfarction was 
fatal, and in 349 (10.4%) it was nonfatal. There were 17 
patients who had a nonfatal reinfarction and later a fatal 
reinfarction; these patients were counted in each category. 
Nonfatal reinfarction. Life-table rates of nonfatal reinfarc- 
tion by specified baseline characteristics over the 3-year follow- 
up period are presented in Table 1 (univariate analysis), and 
the rates of nonfatal reinfarction are shown in Figure 1. 
Fifty-eight percent of the total events occurred within the 
initial 6 weeks of follow-up. During this time period, nonfatal 
reinfarction was predicted by age ->65 years, history (before 
the index event) of angina or of previous myocardial infarction, 
by being a never and not a current smoker and, in patients 
assigned to the invasive strategy, by multivessel coronary artery 
disease. Over the time course of the 3-year follow-up, the 
degree of significance of the univariate predictors f r nonfatal 
reinfarction declined, except forhistory of hypertension. Inde- 
pendent predictors of nonfatal reinfarctions, which occurred 
within 6 weeks, were history (before the index event) of angina 
(relative risk [RR] t.7, 99% confidence interval [CI] 1.1 to 2.5, 
p < 0.001) and not a current smoker (RR 1.9, 99% CI 1.2 to 
2.8, p < 0.001). For nonfatal reinfarctions that occurred within 
3 years, not a current smoker was the only independent 
predictor (RR 1.3, 99% CI 1.0 to 1.8, p = 0.01). In a separate 
analysis of 42-day survivors f ee of nonfatal reinfarction, none 
of the baseline characteristics remained univariate predictors 
of nonfatal reinfarction between 43 days and 3 years. A patent 
infarct-related artery tended to occur more often in patients 
with nonfatal reinfarction: patent artery (n = 1,167) versus 
occluded artery (n = 204) at 1 year, 2.6% versus 1.0%; at 2 
years, 4.9% versus 1.5%; and at 3 years, 5.8% versus 2.1% 
(p = 0.05). 
Death after nonfatal reinfarction. Forty-three of the 349 
patients with a nonfatal reinfarction died during follow-up. By 
the end of the 3-year time course, the life-table mortality rate 
subsequent to nonfatal reinfarction was 14.1% compared with 
7.9% (p < 0.01) in a matched control group (Fig. 2). The risk 
for death after nonfatal reinfarction varied during the 3-year 
follow-up period (Table 2). Within 42 days after study entry, 
the risk ratio for death was 1.9 higher for patients with a 
nonfatal reinfarction than for patients without such an event, 
comparable to the risk ratios of established predictors of death, 
including advanced age, tachycardia, hypotension, history of 
previous myocardial infarction, diabetes and female gender. 
Between 43 and 365 days after study entry, the risk ratio was 
6.2, significantly higher (p < 0.001) than that for the initial 6 
weeks. Subsequent to 1year of follow-up, the risk of death was 
not significantly higher for patients with a nonfatal reinfarction 
than for those without such an event. 
For the 3-year follow-up period, univariate predictors of 
death after nonfatal reinfarction were age ->65 years, the "not 
low risk category" (16) during the index infarction and a 
history of heart failure antedating the index infarction (Table 
3). Death rates tended to be higher in patients with an anterior 
wall myocardial infarction, a history (before the index event) of
myocardial infarction and, in patients assigned to the invasive 
strategy, an ejection fraction <40%. Among these univariate 
predictors, age ->65 years was the only independent predictor 
of death after a nonfatal reinfarction (RR 5.4, 99% CI 2.3 to 
12.4, p < 0.001). 
Discuss ion  
For a nonfatal event to be useful as component of a 
composite nd point, it must occur with sufficient frequency to 
increase the total event rate substantially, and it must be a 
marker for an unsatisfactory clinical outcome. For example, 
the GISSI-2 (25) study used the composite nd point of death, 
new onset of heart failure and extensive left ventricular 
damage. The TIMI 3 trial (26) on unstable angina applied the 
composite nd point of death, reinfarction and documented 
recurrent myocardial ischemia. Death and the occurrence of 
adverse clinical events (stroke, einfarction, recurrent isch- 
emia, heart failure) and adverse angiographic events (lack of 
acute patency or reocclusion of the infarct-related artery) was 
the combined end point in the TAM1 5 trial (27). The TIMI 5 
trial (28) used death, reinfarction and lack of complete reper- 
fusion as the primary end point. In the PAMI study (29), the 
combined end point consisted of death, reinfarction a d 
recurrent ischemia. Among these nonfatal end points, reinfarc- 
tion is probably the simplest and most reliably obtained. 
Incidence of nonfatal reinfarction. The incidence of non- 
fatal reinfarction does not seem to have changed considerably 
with the advent of thrombolytic therapy. Before the use of this 
therapy, the Multicenter Postinfarction Study (12) and the 
Postinfarction Registry of Gilpin et al. (13) reported inci- 
dences of nonfatal reinfarction between hospital discharge and 
1 year of 4.3% and 4.7%, respectively. These results are similar 
to the rate of 3.7% between 2 weeks and 1 year after study 
entry in TIMI II. In placebo-treated patients of the Multi- 
center Diltiazem Postinfarction Trial (14), the nonfatal re- 
infarction rate from study entry to an average follow-up of 
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Table 1. Nonfatal Reinfarction Life-Table Rate by Specified Baseline Characteristics 
No. of 6 wk p 1 yr p 2 yr 3 yr p 
Pts (%) Value (c/;) Value (%) (%) Value 
All pts 3,339 
No. of pts with events 349 (~.2 8.8 10.6 11.3 - -  
Gender 
Male 2,742 5.9 0.08 8.5 0.10 10.4 11.1 0.35 
Female 597 7.8 10.6 11.6 12.2 
Age 
->65 yr 859 8.2 0.008 10.8 0.02 12.3 13.0 0.06 
<65 yr 2,480 5.5 8.2 10.0 10.7 
Anterior MI 
Yes 1.7311 5.7 0.19 8.2 0.20 9.9 10.9 0.12 
No 1.609 6.8 9.5 11.3 12.3 
Risk group (TIMI 11 [rcf. 16]) 
Love risk 1,113 5.4 0.20 8.3 0.40 9.9 10.0 0.53 
Not low risk 2,226 6.6 9.1 10.9 11.5 
History before index MI 
Hypertension 
Yes 1,279 7.3 I).(15 111.6 0.007 12.4 13.0 0.01 
No 2,059 5.5 7.8 9.5 10.3 
Angina 
Yes 1,798 7.8 < (I.0(11 1(I.2 0.003 11.9 12.5 0.01 
No 1,539 4.3 7.3 9.0 9.9 
Previous MI 
Yes 468 9.3 11.(1(15 11.7 0.02 13.8 14.2 0.03 
No 2,871 5.7 8.4 10.1 10.8 
Diabetes 
Yes 439 7.0 0.47 9.7 0.55 12.5 12.9 0.27 
No 2,899 6.1 8.7 10.3 11.1 
CHF 
Yes 92 8,4 (I.45 12.3 0.31 15.2 15.2 0.27 
No 3.246 6.1 8.8 10.5 11.2 
Ever smoker 
Yes 2,565 5.6 (I.0(17 8.4 I).07 10.0 10.6 0.03 
No 768 8.3 1(/.5 12.6 13.7 
Current smoker 
Yes 1,6411 4.2 < 0.001 7.4 0.002 9.0 9.7 0.003 
No 1.693 8.1 10.3 12.1 12.9 
SBP <100 mm ttg 
Yes 187 5.4 0.64 7.3 0.47 10.(t 11.0 0.82 
No 3,152 6.2 8.9 10.6 11.3 
Heart rate >811 beats/rain 
Yes 1,122 5.3 (I.13 7.7 0.09 9.6 10.1 0.17 
No 2,216 e,.6 9.5 11.0 11.8 
lnvasive strategy* 1,5(111 
No. of pts with events 157 
Infarct-related after' 
Occluded 225 5.4 0.62 6.3 0.27 6.9 7.4 0.10 
Patent 1,272 6.3 8.8 10.9 11.7 
Multivessel CAD 
Yes 473 9.0 0.002 11.7 0.002 13.2 14.3 0.007 
No 976 4.8 6.8 8.8 9.5 
Ejection fraction 
<4(1% 3111 7.3 0.54 9.7 0.52 11.9 14.3 0.21 
->40% 1,007 6.2 8.4 10.2 10.7 
* Protocol catheterization performed. CAD = coronary artery disease: CHF = congestive h art failure; MI - myocardial 
infarction; Pts (pts) patients; ref. = reference; SBP systolic blood pressure; TIMI - Thrombolysis in Myocardial 
Infarction. 
25 months was 9.4%, comparable to a rate of 10.8% within 2 similar to that observed in other thrombolytic trials. Nonfatal 
years in TIMI II. reinfarction occurred in 2.5% of hospital survivors in GISSI-2 
The incidence of reinfarction in TIMI II also appears to be at 6 months (30) and in 4.2% of TAMI 1 patients at 1 year (31), 
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Figure l. Three-year cumulative rate of nonfatal 
reinfarction. 
similar to the rates in T1MI II, 2.7% between 2 weeks and 6 
months and 3.7% between 2 weeks and 1 year. The 2-year 
follow-up of hospital survivors of patients in the pooled TAMI 
studies revealed a 5.1% incidence of nonfatal reinfarction (32) 
compared with the rate of 5.5% in TIMI II between 2 weeks 
and 2 years. In TIMI II, most of the nonfatal infarctions 
occurred in the first several weeks after study entry, and the 
rate then declined markedly (Fig. 1), a pattern that has been 
observed for a variety of complications occurring after myo- 
cardial infarction (19,31-33). 
Nonfatal infarction as an independent risk factor. There is 
considerable information from the prethrombolytic era that 
recurrent nonfatal myocardial infarction is a risk factor for 
subsequent mortality. Benhorin et al. (14) reported that non- 
fatal reinfarction was a significant i dependent risk factor for 
subsequent cardiac mortality with a relative risk of 3.0 in 
patients assigned to the placebo arm of the Multicenter 
Diltiazem Postinfarction Trial. Indeed, they found that the 
excess risk contributed by nonfatal reinfarction was greater 
than that contributed by pulmonary congestion and a de- 
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Figure 2. Three-year cumulative rate of death in 
patients after nonfatal reinfarction (solid line) com- 
pared with that of a matched control group (dashed 
line). MI = myocardial infarction. 
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Table 2. Risk Ratios for Death Within 3 Years 
Risk Confidence 
Variable Ratio Inter~'al 
Nonfatal reinfarction 
Within 42 d*~ 1.89 1.11-3.23 
43 d-I yr:[: 6.22 3.00-12.88 
366 d-3 yr 2.~0 11.63-13.35 
Age ->65 yr 2.21 1.65-2.98 
Not low risk group (TIMI II [ref. 16]) 2.00 1.311-3.117 
Heart rate >80 beats/min 1.~)3 1.45-2.57 
Hypotension (SBP < 100 mm Hg) 1.82 I. 15-2,88 
MI before index event 1.81 1.31/-2.53 
Diabetes 1.77 1.26-2.47 
Female gender 1.41 1.02-1.95 
*p < 0.001 versus 43 days (d) to 1 },'ear. "}'p = [I.4t) -+p = 11.24 versus 366 days 
to 3 years. Other abbreviations as in Table 1. 
pressed ejection fraction (14). Similarly, Kornowski et al. (34) 
found reinfarction to be the most powerful predictor of 
long-term total mortality in the Secondary Prevention Rein- 
farction Israel Trial (SPRINT) Registry, (34), with an adjusted 
relative risk of 4.7. In the SAVE trial 135), the relative risk of 
subsequent mortality for patients with nonfatal recurrent myo- 
cardial infarction was 3.6. 
The present analysis shows that nonfatal reinfarction also 
has an adverse effect on survival in patients who have received 
thrombolytic therapy. Nonfatal reinfarction had the greatest 
prognostic impact within the first year of follow-up, in partic- 
ular after hospital discharge. The risk ratio for death within the 
initial 42 days after the index event was 1.9 compared with 6.2 
(p < 0.001) between 43 days and 1 year. This finding can bc 
considered supportive of the observation that reinfarction 
early after thrombolysis frequently represents reocclusion of 
the infarct-related artery and thus completion of an inter- 
rupted infarction (36,37), whereas later occurring reinfarction 
is considered to represent more often progression of coronary 
artery disease. Myocardial d mage caused by completion of an 
interrupted infarction is likely to be less severe than myocar- 
dial damage caused by a new infarction potentially distant from 
the index event. The risk ratio for death after a nonfatal 
reinfarction of 1.9 within the initial 42 days of follow-up was 
comparable to those of baseline variables well known to have 
an adverse effect on outcome, such as advanced age, diabetes 
and female gender, as well as of events occurring in the course 
of the index myocardial infarction, such as heart rate >80 
beats/rain and hypotension (24). 
The adverse prognostic impact of nonfatal reinfarction 
emphasizes the importance of identifying patients at risk for 
this event. Prediction of reinfarction (fatal and nonfatal com- 
bined) has been ditficult in the past (15,24,36-39). In GISSI-2, 
a history of angina or myocardial infarction before the index 
infarction and ineligibility for exercise t sting as well as the 
presence of angina at follow-up were predictors of reinfarction 
(30). In the present analysis of TIMI II, characteristics ug- 
gesting the presence of extensive coronary artery disease, such 
Table 3. Death Life-Table Rate by Specified Baseline 
Characteristics in Patients With Nonfatal Reinfarction 
No. of 6wk lyr  2yr 3yr p 
Pts (%) (%) (%) (%) Value 
All pts 349 
Pts with events 43 5.2 8.5 12.2 14.1 - -  
Gender 
Male 283 5.11 8.7 12.1 14.6 0.88 
Female 66 6.1 7.7 12.4 12.4 
Age 
>65 yr 100 14.1 18.2 27.2 29.1 <0.001 
<65 yr 249 1.6 4.5 6.0 7.9 
Anterior MI 
Yes 164 6.7 12.3 15.8 18.5 0.03 
No 185 3.8 4.9 8.9 10.2 
Risk group (TIM1 II [ref. 16]) 
Low risk 115 1.8 1.8 6.0 8.3 0.015 
Not low risk 234 6.9 11.7 15.2 17.0 
Historv before index Ml 
1 lypertension 
Yes 153 5.2 8.5 13.6 13.6 0.85 
No 196 5.2 8.4 11t.9 14.6 
Angina 
Yes 2119 4.4 8.8 12.6 14.5 11.80 
No 140 6.5 8.0 11.7 13.4 
Pre~,ious MI 
Yes 60 6.8 17.0 20.8 20.8 0.05 
No 289 4.9 6.7 10.3 12.7 
Diabetes 
Yes 50 6.0 14.1 21.1 21.1 0.09 
No 299 5.1 7.5 10.6 13.0 
CHF 
Yes 12 1).0 25.0 41.7 51.4 <0.001 
No 337 5.4 7.9 11.0 12.5 
Ever smoker 
Yes 254 5.2 8.8 12.6 15.3 0.54 
No 95 5.3 7.5 11.1 11.1 
Current smoker 
Yes 147 4.1 7.6 11.7 14.8 0.98 
No 202 6.0 9.1 12.5 13.7 
SBP <100 mm Hg 
Yes 17 5.9 11.8 11.8 22.8 0.49 
No 332 5.2 8.3 12.1 13.6 
Heart rate >81) beats/rain 
Yes 1113 7.8 12.8 16.0 17.8 0.13 
No 245 4.1 6.7 10.6 12.5 
lnvasivc strategy* 157 
Pts with events 21 
Infarct-related artery 
Occluded 16 6.3 12.5 12.5 12.5 0.91 
Patent 141 4.3 7.2 12.9 16.0 
Multivessel CAD 
Yes 63 4.8 11.3 16.7 20.2 
No 88 4.6 5.7 9.6 11.6 0.21 
Ejection fraction 
<4!i~:4 39 5.2 13.2 19.2 29.5 0.03 
_>40% 104 3.8 5.8 10.2 10.2 
*Protocol catheterization performed. Abbreviations as in Table 1. 
as advanced age, history of angina, hypertension or myocardial 
infarction before the index infarction, as well as multivessel 
disease at coronary angiography after the infarction, were 
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univariate predictors of nonfatal reinfarction (Table 1). The 
only independent predictors of nonfatal reinfarction were 
history of angina and not being a smoker at the time of the 
index infarction. These univariate and independent predictors 
were strongest for nonfatal reinfarctions that occurred within 6 
weeks after the index infarction, when >50% of the events 
were observed (19,31,32). Not being a current smoker has 
earlier been reported to be a risk factor for fatal and nonfatal 
reinfarction combined and to be a risk factor for death in 
patients with a myocardial infarction whoreceived thrombo- 
lytic therapy (24,40). In contrast, before the thrombolytic era, 
cigarette smoking was n established risk factor for myocardial 
infarction and reinfarction (41), and continuation of smoking 
worsened (42), whereas discontinuation f smoking improved, 
long-term outcome (43). These apparently contradictory find- 
ings are difficult o explain. The fact that smokers experience 
their infarction and recurrent infarction at a younger age and 
present with a more favorable risk profile compared with not 
current smokers may, in part, explain the "better" outcome in 
current smokers (24,40). 
It has been observed in both the prethrombolytic and 
thrombolytic eras that left ventricular failure (7,19,31,36,44,45) 
and advanced age (19,36,45) are the most powerful predictors 
of death after myocardial infarction. In the present analysis, 
advanced age and left ventricular dysfunction were predictors 
of death subsequent to nonfatal reinfarction as well, but age 
->65 years was the only independent predictor. 
Conclusions. Nonfatal reinfarction is an end point that can 
be documented relatively easily and reliably. The present 
analysis of a 3-year follow-up of patients enrolled in the TIMI 
II trial demonstrates that the rate of nonfatal reinfarction is
highest within the early period after the index infarction and 
that nonfatal reinfarction is a strong and independent predic- 
tor of fatal outcome, in particular within the first year of 
follow-up. Therefore, in patients who receive thrombolytic 
therapy after acute myocardial infarction, nonfatal reinfarction 
represents a powerful and useful component of a combined 
end point. 
We thank Yolanda Vasquez for assistance in preparation of the manuscript. 
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